Simultaneous detection and epitope mapping of anti-factor VIII antibodies

Summary

The development of antibodies (Abs) against infused factor VIII (FVIII) is currently one of the most serious complications in the treatment of patients suffering from haemophilia A. Improved prevention and eradication of these anti-FVIII Abs remain a challenge for both clinicians and scientists. Here we describe an immunoassay to simultaneously detect and map the epitope specificity of haemophilia A patients’ inhibitors by screening plasma against both heavy and light chains (HC and LC) of human plasma-derived FVIII (pFVIII). The format used was a two-site sandwich assay, where one monoclonal antibody (mAb) specific for the HC or LC was first immobilized on beads, and then incubated with the different forms of pFVIII. After incubation with patients’ plasma samples, binding was revealed by a phycoerythrin-labeled secondary Ab. Samples from haemophilia patients with autoantibodies (autoAb) or alloantibodies (alloAb) were screened in this format. The former preferentially recognized the LC, whereas the latter were directed against both LC and HC. This technology appears attractive as it is fast and requires only 100 μl of patient’s plasma. Furthermore, not only are anti-FVIII Abs detected, but information on their epitopic specificity is also obtained.

Keywords

Haemophilia A - inhibitors - epitope mapping

^* These authors contributed equally to this work.

• References

• 1 Lavigne-Lissalde G. et al. Anti-factor VIII antibodies: a 2005 update. Thromb Haemost 2005; 94: 760-769.
• 2 Ehrenforth S. et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
• 3 Hoyer LW, Hemophilia A. N Engl J Med 1994; 330: 38-47.
• 4 Kasper CK, Pool JG. Measurement of mild factor VIII inhibitors in Bethesda units. Thromb Diath Haemorrh 1975; 34: 875-876.
• 5 Kazatchkine MD. et al. Circulating immune complexes containing anti-VIII antibodies in multi-transfused patients with haemophilia A. Clin Exp Immunol 1980; 39: 315-320.
• 6 Sahud MA. et al. ELISA system for Detection of Immune Responses to Factor VIII: a study of 246 samples and correlation with the Bethesda assay. Hemophilia 2007; 13: 317-322.
• 7 Towfighi F. et al. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol 2005; 114: 84-90.
• 8 Shetty S. et al. ELISA for factor VIII antibodies: does it detect antibodies much before the conventional Bethesda assay?. Haemophilia 2003; 9: 654.
• 9 Martin PG. et al. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol 1999; 21: 125-128.
• 10 Wight J. et al. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 436-463.
• 11 Collins PW. Novel therapies for immune tolerance in haemophilia A. Haemophilia 2006; 12: 94-101.
• 12 Dimichele DM. Management of factor VIII inhibitors. Int J Hematol 2006; 83: 119-125.
• 13 Acharya SS, DiMichele DM. Management of factor VIII inhibitors. Best Pract Res Clin Haematol 2006; 19: 51-66.
• 14 Goudemand J. Hemophilia. Treatment of patients with inhibitors: cost issues. Haemophilia 1999; 5: 397-401.
• 15 Auerswald G. et al. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
• 16 Kreuz W. et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.
• 17 Orsini F. et al. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-1290.
• 18 Gringeri A. et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-379.
• 19 Greninger DA. et al. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia. 2008 in print.
• 20 Kurth MA. et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50-55.
• 21 Waterboer T. et al. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 2006; 309: 200-204.
• 22 Fulton RJ. et al. Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 1997; 43: 1749-1756.
• 23 Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem 1997; 272: 18007-18014.
• 24 Lavigne-Lissalde G. et al. Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice. Thromb Haemost 2007; 98: 138-147.
• 25 Jacquemin MG. et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998; 92: 496-506.
• 26 Giles AR. et al. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1998; 79: 872-875.
• 27 Kessler CM. Acquired factor VIII autoantibody inhibitors: current concepts and potential therapeutic strategies for the future. Haematologica 2000; 85: 57-61.
• 28 Dimichele D. Factor VIII pharmacokinetics: impact of low titer non-neutralizing inhibitors and use in determination of successful immune tolerance. Haemophilia 2006; 12: 56-60.
• 29 Lollar P. Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules. Haematologica 2000; 85: 26-28.
• 30 Scandella D. Human anti-factor VIII antibodies: epitope localization and inhibitory function. Vox Sang 1996; 70: 9-14.
• 31 Scandella D. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies. Vox Sang 1999; 77: 17-20.
• 32 Collins PW. et al. Acquired haemophilia A in the UK: a two year national surveillance study by UK Haemophilia Centre Doctors' Organisation. Blood 2006; 105: 1870-1877.
• 33 Bray GL. et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-2435.
• 34 Fischer K. et al. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?. Haemophilia 2004; 10: 216-220.
• 35 Fulcher CA. et al. Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood 1988; 72: 1348-1356.
• 36 Shima M. Characterization of factor VIII inhibitors. Int J Haematol 2006; 83: 109-118.
• 37 Prescott R. et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89: 3663-3671.